Active Biotech Secures European Patent for Tasquinimod in Myelofibrosis

The latest announcement is out from Active Biotech AB ( (SE:ACTI) ).

Active Biotech announced that the European Patent Office has granted a patent for tasquinimod in the treatment of myelofibrosis, a rare blood cancer, providing market exclusivity in Europe until 2041. This patent is a significant milestone in the development of tasquinimod, enhancing Active Biotech’s position in the hematological malignancies market and potentially benefiting stakeholders by advancing treatment options for myelofibrosis.

More about Active Biotech AB

Active Biotech AB is a biotechnology company focused on developing first-in-class immunomodulatory treatments for oncology and immunology, targeting high unmet medical needs. The company has a portfolio that includes tasquinimod and laquinimod, small molecule immunomodulators, and naptumomab, a targeted anti-cancer immunotherapy. Active Biotech’s core focus is on developing tasquinimod for myelofibrosis, a rare blood cancer, and is also advancing laquinimod for non-infectious uveitis.

Average Trading Volume: 10,892,048

Current Market Cap: SEK144.2M

Learn more about ACTI stock on TipRanks’ Stock Analysis page.